Doc,
The only time I believe the regulators ever comment on anything involving a company beyond their actions on official documents is if the company misrepresents what they're being told by, or doing with, the regulators. They simply don't update stockholders and they won't be intimidated by them.
For those who remember DNDN, the shareholders tried all sorts of things to push the approval of Provenge. When DNDN met their demand it was approved, but all the threats to go to Congress, the Supreme Court, etc. had no apparent effect on the FDA and frankly I wouldn't be surprised if it slowed them down.
NWBO has been more secretive about their plans than most, but really not all biotech's, very few are so open with investors that at least some investors don't complain. When a company is very open, like CVM, I urge caution with believing what they're saying.
The end of this month, or early next, we'll get a quarterly, it at least provides an opportunity for the company to update the shareholders. Let's hope they take it and give us some guidance for at least what the remainder of the year should hold.
Gary
Bullish
Market Data 
Markets 
AI
